Esperion Therapeutics, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Accelerated filer
State of Incorporation DE
Business Address 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI, 48108
Mailing Address 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI, 48108
Phone 734-887-3903
Fiscal Year End 1231
EIN 000000000
Financial Overview
FY2024
$343.82M
Total Assets
$732.54M
Total Liabilities
$144.76M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | January 21, 2026 | View on SEC |
| 8-K Current report of material events | January 12, 2026 | View on SEC |
| 4 Insider stock transaction report | December 18, 2025 | View on SEC |
| 4 Insider stock transaction report | December 18, 2025 | View on SEC |
| 4 Insider stock transaction report | December 18, 2025 | View on SEC |
| 4 Insider stock transaction report | December 8, 2025 | View on SEC |
| 3 Initial insider ownership report | November 17, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 14, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 12, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 6, 2025 | View on SEC |
Insider Trading
SELL 3 insiders
4 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.